28 results about "In vitro test" patented technology

The invention discloses a method and a system for testing corrosion fatigue of a bone implantation device under a pathological condition, and relates to the technical field of orthopedic medical device evaluation, and the method comprises the following steps: constructing a dynamic load spectrum database covering physiological and pathological states; in-vitro reproduction of a dynamic mechanical environment borne by the bone implantation instrument in physiological and pathological states is completed through a multi-axis servo system; and acquiring service state data of the bone implantation instrument, and analyzing the service state data of the bone implantation instrument to obtain coupling experiment data. According to the invention, the defects of single load mode and environment simulation distortion in the traditional test method are overcome, high-fidelity simulation and comprehensive monitoring of the corrosion fatigue behavior of the bone implantation device under the pathological condition are realized, the consistency of the in-vitro test result and the in-vivo actual service performance is improved, and the application prospect is wide. And a scientific and unified evaluation basis is provided for material screening, structure optimization and service life evaluation of different types of bone implantation instruments.

Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein.Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant.Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone. Relacorilant and such reduced doses of paclitaxel may be co-administered to treat cancer, e.g., ovarian or pancreatic cancer.

Relacorilant is useful in the treatment of hypercortisolism and cancer. Many drugs useful in treating hypercortisolism or cancer are metabolized by CYP2C9 enzymes. The effects of concomitant administration of relacorilant and a CYP2C9 substrate are disclosed herein.Relacorilant potently inhibited CYP2C9 in an in vitro test, indicating that co-administration of relacorilant and a CYP2C9 substrate would be expected to increase the CYP2C9 substrate plasma exposure more than five-fold in vivo. Significant reductions in CYP2C9 substrate doses would be expected to be required when administered with relacorilant.Surprisingly, no such increase in plasma exposure was seen in human studies. Applicant discloses that relacorilant may be safely co-administered with unmodified doses of a CYP2C9 substrate such as, e.g., tolbutamide, glimepiride, and glipizide. Relacorilant and unmodified doses of CYP2C9 substrate such as tolbutamide, glimepiride, and glipizide may be co-administered to treat hypercortisolism, or may be co-administered to a cancer patient.

The present invention provides a sunscreen composition comprising: (i) TiO2, (ii) ZnO, (iii) triacontanyl PVP, and (iv) VP / hexadecene copolymer, wherein the composition is an oil-in-water emulsion substantially free of low molecular weight, organic UV absorbers, the ratio of (iii):(iv) is less than one, and the composition provides an in vitro SPF as measured by the IN VITRO SPF TEST METHOD of at least 25. The composition is surprisingly low viscosity and provides a high SPF.

The invention belongs to the technical field of biological detection, and provides a multiple cell factor detection kit in macrophage polarization and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture system is used for preparing a capture antibody coupled with a fluorescence coding microsphere by coupling a biotinylated antibody with a fluorescence microsphere coated with biotin, and the detection system is used for preparing a fluorescence labeled antibody by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody. The mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect multiple cell factors, the sample dosage is only 25 microliters, the kit is suitable for in-vitro tests of mouse mononuclear macrophage leukemia cell lines RAW264.7, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of being high in throughput, wide in linear range and high in stability.

An ex vivo test system 10 is constituted of a fluid circuit that circulates a prescribed circulation liquid by simulating the blood circulation state of a human body, and comprises a circulation liquid maintenance unit 17 that maintains, in the same manner as the blood environment in vivo, chemical factors in the circulation liquid, which affect the performance evaluation of a test object S. The circulation liquid maintenance unit 17 comprises: a replenishing liquid unit 23 that maintains the chloride ion concentration and protein concentration of the circulation liquid at desired values by injecting a replenishing liquid composed of an electrolyte-free isotonic solution into the fluid circuit; and a carbon dioxide supply unit 24 that maintains the pH of the circulation liquid at a desired value by supplying carbon dioxide into the fluid circuit, the state of the circulation liquid being maintained while compensating for the effect of moisture loss during circulation of the circulation liquid.

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (Dol) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

This invention relates to the field of medical device technology, and in particular to an in vitro testing phantom, in vitro testing system, and method for assessing the application accuracy of a robot system. The in vitro testing phantom includes a first phantom with a first positioning point for inserting a test specimen; and a second phantom adapted to the first phantom and having a second positioning point. After the first and second phantoms are installed, the relative positions of the first and second positioning points are determined, and the projections of the first and second positioning points relative to the same plane at least partially overlap. Its advantage lies in that the first and second positioning points can cooperate to form a channel through which the test specimen can pass, thereby testing the application accuracy of the robot system. Only by changing the shape and size of the second positioning point can the accuracy requirements for the test specimen be changed, thus expanding the application range of the testing phantom.

This invention discloses a semi-sandwich structured ruthenium triphenylphosphine dithiocarboxylic acid complex with a simple preparation process and its applications. The complex has the structure shown in Figure (I), with the central ruthenium and... η 5 - Coordination with cyclopentadiene, triphenylphosphine, and dithiocarboxylic acid derivatives, wherein the dithiocarboxylic acid ligands are selected from ethyl xanthic acid, isopropyl xanthic acid, ... N,N Diethyldithiocarbamic acid, morpholine dithiocarbamic acid, and carbazole dithiocarbamic acid. This invention employs a simple one-step method of room temperature preparation and recrystallization purification using a ruthenium precursor and dithiocarbamic acid ligand. This method offers advantages such as readily available raw materials, mild reaction conditions, simple post-processing, and high yield. In vitro tests show that the complexes exhibit excellent anti-proliferative activity against non-small cell lung cancer A549 cells, significantly superior to cisplatin. The complexes demonstrate activity by reducing mitochondrial membrane potential, inducing intracellular reactive oxygen species accumulation, and arresting the cell cycle (G1 phase), leading to late apoptosis in A549 cells.

The present application relates to the technical field of veterinary medicine preparation, and particularly relates to a water-soluble medicine gastro-resistant and enteric-coated granule, a preparation method and application thereof, the coated granule comprising: an inner core of at least one water-soluble medicine active ingredient, a coating layer coated outside the inner core; and the coating layer is formed by a composite coating material of hydrogenated palm oil and lipophilic hydrophobic nano active light calcium carbonate. The present application has the advantages that the nano calcium carbonate is used to form pores in the true stomach by acid reaction and to produce gas by saponification with fatty acids in the intestinal tract, so that the water-soluble medicine is efficiently protected in the rumen and rapidly and completely released in the intestinal tract. In vitro tests show that the effective release rate can reach more than 79%, which is significantly better than the traditional coating, and has a broad clinical application prospect.

This invention relates to the field of computational toxicology, and in particular to a precise method for comparing the consistency of animal and non-animal toxicity evaluation results. This method acquires in vivo baseline data from animals and in vitro test data from non-animals. It employs a dynamic time warping algorithm and radial basis function kernel function to construct correction coefficients and perform equivalent mapping to generate a converted sequence. Based on a binary classification mapping of toxicity thresholds, a confusion matrix is ​​constructed to calculate sensitivity, specificity, and predicted values. Each indicator is treated as an independent source of evidence, and the Mahalanobis distance is calculated using the covariance matrix to generate a basic probability allocation function. The D-S evidence theory combination rule is applied for fusion, and a secondary factor allocation is introduced when there is conflict. Finally, the result is compared with a preset threshold to determine the feasibility of substitution. This invention adaptively eliminates the nonlinear misalignment difference between in vivo and in vitro dose responses, providing an objective quantitative judgment standard for toxicological substitution verification.

The invention provides an isophorone dye derivative LYC-CF3 as well as a synthesis method and application thereof. The specific name of the isophorone dye derivative is (E)-4-(2-(3-(dicyanomethylene)-5, 5-dimethylcyclohex-1-ene-1-yl) vinyl)-2-(trifluoromethyl) phenyl trifluoromethanesulfonate, and the structural formula of the isophorone dye derivative is shown in the description. The invention also provides a synthesis method of the derivative LYC-CF3, and a fluorescence imaging experiment of the derivative LYC-CF3 on O2 <-> in PC-12 cells. Through verification of a fluorescence spectrum and a laser confocal microscope, the derivative LYC-CF3 has quick response to O2 <-> in an in-vitro test and cells and relatively remarkable fluorescence imaging capability. Therefore, LYC-CF3 can be used as a fluorescent probe for in-vitro detection of O2 <-> and detection of O2 <-> in cells.

The present disclosure provides a system, device, control method and storage medium for simulating physical characteristics of blood vessels. The method for simulating physical characteristics of blood vessels comprises determining blood vessel types of a lesion to be studied, collecting clinical medical data of the lesion blood vessels, performing isolated modeling on each blood vessel branch, setting initial reference values of the model, connecting the blood vessel model and the device for simulating physical characteristics of blood vessels to an in-vitro test device, operating the in-vitro test device based on the initial reference values, and calculating blood vessel resistance, compliance and test temperature in the blood vessel model in real time according to sensor collected data, and calculating differences between target values and corresponding measured values. The in-vitro test device is adjusted through a simulated neural feedback mechanism and a direct coordination mechanism of each blood vessel branch until the differences between the target values and the corresponding measured values meet predetermined conditions.

The present invention provides a sunscreen composition comprising: (i) TiO2, (ii) ZnO, (iii) triacontanyl PVP, and (iv) VP / hexadecene copolymer, wherein the composition is an oil-in-water emulsion substantially free of low molecular weight, organic UV absorbers, the ratio of (iii):(iv) is less than one, and the composition provides an in vitro SPF as measured by the IN VITRO SPF TEST METHOD of at least 25. The composition is surprisingly low viscosity and provides a high SPF.

The application provides a use of a banana tissue endogenous hormone zeatin in resisting banana wilt, and belongs to the technical field of plant protection. The banana tissue endogenous hormone is zeatin, and experiments prove that in vitro tests (tissue culture bottles and greenhouses) of the zeatin or lutein show that the zeatin can effectively inhibit the growth of TR4 mycelium, exhibits good anti-banana wilt fungus activity, has a significant prevention and control effect on the banana wilt fungus (TR4), and does not affect the growth of seedlings. The application provides a new idea and method for preventing and controlling TR4, and lays a foundation for in-depth exploration of the prevention and control of the banana wilt disease TR4.

The invention relates to the field of biological medicine, in particular to a three-component platinum (IV) complex containing captopril (CTP) and valproic acid (VPA), a preparation method of the three-component platinum (IV) complex and application of the three-component platinum (IV) complex in preparation of anti-tumor proliferation and anti-metastasis drugs. The anti-tumor proliferation and anti-metastasis effects of the target compound are tested through in-vivo and in-vitro testing means, and the anti-tumor mechanism of the medicine is researched. Results prove that the compound has a remarkable anti-tumor capability, particularly has an excellent treatment effect on metastatic malignant tumors, is expected to provide a new candidate drug for clinical treatment of tumors, and provides a new direction for research and development of novel platinum drugs and anti-tumor metastasis drugs.

The present application relates to the technical field of probiotic preparation, and particularly relates to a gastroenteric probiotic granule and a preparation method and application thereof, the coated granule comprises: a probiotic core material, and a coating layer coated outside the core material; the coating layer is formed by a composite coating material of hydrogenated palm oil and stearic acid surface modified nano active calcium carbonate, wherein the stearic acid surface modified nano active calcium carbonate accounts for 50% to 60% of the total mass of the composite coating material, and the weight ratio of the coating layer to the core material is 20% to 25%. The present application utilizes hydrogenated palm oil to form a hydrophobic physical barrier, and simultaneously utilizes nano calcium carbonate to slowly neutralize acidity in gastric acid, generate bubbles to form a microenvironment buffer, and realize a dual synergistic protection mechanism of physical barrier and chemical buffer. In vitro tests show that the probiotic granule prepared by the present application has a survival rate of greater than or equal to 90% after being treated in artificial gastric juice for 2 hours, and a release rate of greater than or equal to 93% after being treated in artificial intestinal juice for 2 hours, which is significantly better than traditional coating technology, and has a broad industrial application prospect.

The invention aims to disclose a preparation method and application of a biological fluorescent probe for detecting heavy metal silver ions. Silver is a high-toxicity heavy metal pollutant, excessive release in the environment and long-term accumulation in a living body can cause serious influence on an ecological system and human health. In recent years, a small organic molecule-based fluorescent sensing system and a nano fluorescent sensing system have gradually detected silver ions, but the design method is often complicated in synthesis method and is not suitable for a physiological environment or cannot distinguish other metal ions. Compared with other fluorescent probes, the biological fluorescent probe is widely concerned by researchers due to excellent biocompatibility, low cytotoxicity and excellent recognition capability. Dansyl chloride (DNSCI) is used as a luminous group for polypeptide modification to obtain a novel biological fluorescent probe, and both optical tests and in-vitro tests show that the probe can realize accurate recognition of Ag < + >.

The present invention relates to methods for producing an artificial basement membrane comprising a fiber mesh, artificial basement membranes comprising a fiber mesh, in particular produced by means of the method according to the invention, as well as in vitro test systems, cell culture systems, filtration systems and organ systems comprising at least one artificial basement membrane of the present invention.

To provide a sunscreen composition.SOLUTION: The present invention provides a sunscreen composition comprising (i) TiO2, (ii) ZnO, (iii) triacontanyl PVP, and (iv) a VP / hexadecene copolymer, wherein the composition is an oil-in-water emulsion that is substantially free of low molecular weight organic UV absorbers, wherein the ratio of (iii): (iv) is less than 1, and wherein the composition provides an in vitro SPF of at least 25 as measured by the in vitro SPF test method. The compositions are surprisingly low in viscosity and provide high SPF.SELECTED DRAWING: None

Disclosed herein is a film for receiving an implant formulation for in vitro testing, the film comprising a roughened surface and a scribed area on the roughened surface for receiving an in situ forming implant formulation; the in situ formulation comprising a pharmaceutically acceptable therapeutic molecule, a biodegradable polymer, a water-miscible solvent, or any combination thereof; and where a surface roughness of the roughened surface is operative to control a surface to volume ratio of the in situ forming implant formulation when tested in a dissolution adapter and / or a cassette such that a Level A in vitro-in vivo correlation is obtained.

The present invention provides a sunscreen composition comprising (i) TiO2, (ii) ZnO, (iii) triacontyl PVP, and (iv) a VP / hexadecene copolymer wherein the composition is an oil-in-water emulsion substantially free of a low molecular weight organic UV absorber, (iii): (iv) a weight ratio of less than 1, and the composition provides an in vitro SPF of at least 25 as measured by the in vitro SPF test method. The composition has a surprisingly low viscosity and provides a high SPF.

The invention belongs to the technical field of ultrasonic contrast agents, and discloses a tsamba gastrointestinal ultrasonic contrast agent as well as a preparation method and application thereof. The contrast agent takes Tibet Plateau pure natural tsamba powder as a core matrix, is subjected to superfine grinding and sterilization, is matched with a natural suspension stabilizer, a food-grade defoaming agent and a flavoring agent, and is blended with warm water according to a specific proportion to form a suspension; the preparation process comprises three steps of raw material pretreatment, dry mixing and suspension preparation, and is simple and convenient to operate. By regulating and controlling parameters such as granularity (more than 90% of particles are 10-50 microns) and concentration (8-12g / 100mL warm water) of zanba powder, acoustic characteristics can be adjusted, in-vitro detection shows that the contrast agent is medium-fine in echo, stable in suspension within 30 minutes and free of rear sound attenuation, and a gastrointestinal wall structure can be clearly drawn. The invention has the advantages of high biocompatibility, low side effect, good patient tolerance, nutrition support effect, convenience in storage and transportation and low preparation cost, and is suitable for gastrointestinal ultrasound examination of various crowds.

This invention discloses a systemic circulation venous simulation system, comprising a right ventricular simulation component, an arterial compliance simulation component, a venous vessel module, a damping module, a throttling valve, a collapsible venous segment, a venous compliance simulation component, a right atrial simulation component, a drive module, and a data acquisition module. The right ventricular simulation component simulates the pumping function of the right ventricle; the arterial compliance simulation component simulates the elastic energy storage characteristics of the arterial system; the venous vessel module includes a collecting chamber, a superior vena cava return vessel, an inferior vena cava return vessel, and a vena cava confluence conduit; the collapsible venous segment prevents excessive negative pressure in the venous system; the venous compliance simulation component reduces the impact of right atrial pressure fluctuations on the venous vessels; and the right atrial simulation component simulates the right atrial filling state through internal volume changes. This simulation system can be used for in vitro testing of vena cava intervention devices.

This invention proposes an in vitro testing device for the aortic valve and ascending aorta, comprising a chamber system, a drive system, a circuit system, a chamber auxiliary system, a control system, and a particle image velocimetry system. Based on patient medical images, this device constructs a 1:1 personalized aortic valve and ascending aorta vascular model, realistically simulating an individualized hemodynamic environment through closed-loop pulsatile flow circulation. It can rapidly and quantitatively acquire complex functional parameters such as blood flow velocity, pressure, wall shear force, and relative particle residence time, overcoming the limitations of traditional imaging providing only morphological data and CFD simulation relying on ideal assumptions. Simultaneously, it can be used for individualized in vitro testing of artificial aortic valves, evaluating their performance in specific anatomical structures, significantly improving the accuracy of preoperative planning, postoperative prediction, and device development. This device has advantages such as high physiological fidelity, high testing efficiency, and strong result repeatability, making it suitable for precision cardiovascular diagnosis and treatment and evaluation of implantable interventional devices.

The application relates to the field of biological medicine, and particularly discloses application of RNA pseudouridine modification in preparation of an acute myeloid leukemia in vitro detection product. The application takes the pseudouridine modification level of a specific gene-derived RNA molecule as an inspection index, reflects the molecular changes related to acute myeloid leukemia from the aspect of epitranscription, helps to improve the accuracy of risk assessment of acute myeloid leukemia, and has sensitivity and specificity in distinguishing acute myeloid leukemia and normal controls in terms of the pseudouridine modification level of the RNA molecule corresponding to any one of the PDE3A gene, the DPP9 gene, the SNORD59A gene, the FP236383.1 gene, the SNORD14C gene and the RNU2-6P gene. The application can be applied to the detection of blood or bone marrow and other samples outside the body, the sampling mode is simple, has good accessibility and popularization value, and is favorable for realizing early screening and risk stratification of acute myeloid leukemia.

The application discloses an in-vitro testing device for a micro interventional pump, which comprises an inlet section, a clamping section and an outlet section which are independently designed and hollow inside, the inner diameters of the inlet section and the outlet section are consistent with the inner diameter of a real blood vessel at an implantation position to simulate a mechanical environment in a human body, the clamping section is detachably connected between the inlet section and the outlet section to facilitate installation and replacement, different lengths or cross-sectional shapes of the outlet section are replaced according to the blood vessel morphology at the implantation position to adapt to different testing simulation requirements, the clamping section is curved and the curvature is adapted to the curvature of the micro interventional pump, flexible clamping blocks are arranged inside the clamping section for clamping the micro interventional pump, and sensor interfaces for connecting testing sensors such as pressure sensors and temperature sensors are arranged outside the inlet section and the outlet section. The device can be used for in-vitro testing of various micro interventional pumps, the hemodynamic characteristics of the testing environment are consistent with physiological conditions, the blood compatibility is good, and the device can meet the requirements of in-vitro hemolysis experiments and particle image velocimetry experiments.

The present application relates to an antibacterial product based on olive leaf extract, belonging to the technical field of antibacterial care. The product is based on olive leaf extract rich in polyphenol active ingredients, combined with bacteriostatic polypeptides derived from Xenopus laevis as the core active component, to achieve synergistic antibacterial effect. Studies have shown that the combination has rapid and strong inhibitory and killing ability on common pathogenic microorganisms such as Staphylococcus aureus and Candida albicans, and is significantly better than single component. In vitro test results show that the product can achieve strong bacteriostatic and bactericidal effect in a short time, and has certain sustained bacteriostatic ability. Compared with traditional antibiotics or single plant extract, the present application improves the antibacterial efficiency and reduces the risk of drug resistance through the synergistic mechanism of "natural plant matrix + functional polypeptide", and has good safety and microecological friendliness, and is suitable for daily care and infection protection of female reproductive system.